BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 33925632)

  • 1. Theranostic Advances in Breast Cancer in Nuclear Medicine.
    Vahidfar N; Aghanejad A; Ahmadzadehfar H; Farzanehfar S; Eppard E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted radionuclide therapy: frontiers in theranostics.
    Gallivanone F; Valente M; Savi A; Canevari C; Castiglioni I
    Front Biosci (Landmark Ed); 2017 Jun; 22(10):1750-1759. PubMed ID: 28410143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioligand Theranostics in the Management of Neuroendocrine Tumors.
    Harris AG; Vinik AI; OʼDorisio TM; OʼDorisio MS
    Pancreas; 2020; 49(5):599-603. PubMed ID: 32433395
    [No Abstract]   [Full Text] [Related]  

  • 4. Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.
    Miller C; Rousseau J; Ramogida CF; Celler A; Rahmim A; Uribe CF
    Theranostics; 2022; 12(1):232-259. PubMed ID: 34987643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More.
    Turner JH
    Cancer Biother Radiopharm; 2019 Apr; 34(3):135-140. PubMed ID: 30973278
    [No Abstract]   [Full Text] [Related]  

  • 6. Toward Independent Nuclear Medicine, Molecular Imaging, and Theranostic Programs.
    Czernin J
    J Nucl Med; 2019 Aug; 60(8):1037. PubMed ID: 31371618
    [No Abstract]   [Full Text] [Related]  

  • 7. Theranostic approaches in nuclear medicine: current status and future prospects.
    Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
    Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
    [No Abstract]   [Full Text] [Related]  

  • 8. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology.
    Gomes Marin JF; Nunes RF; Coutinho AM; Zaniboni EC; Costa LB; Barbosa FG; Queiroz MA; Cerri GG; Buchpiguel CA
    Radiographics; 2020 Oct; 40(6):1715-1740. PubMed ID: 33001789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear Medicine Cancer Care-Current Status and Future Directions for Radiopharmaceutical Diagnostics and Theranostics for Cancer.
    O'Brien SR; Mankoff DA
    Cancer J; 2024 May-Jun 01; 30(3):140-141. PubMed ID: 38753747
    [No Abstract]   [Full Text] [Related]  

  • 10. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
    Langbein T; Weber WA; Eiber M
    J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy.
    Jo SD; Ku SH; Won YY; Kim SH; Kwon IC
    Theranostics; 2016; 6(9):1362-77. PubMed ID: 27375785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into the theranostic value of precision medicine on advanced radiotherapy to breast cancer.
    Jiang M; Yang J; Li K; Liu J; Jing X; Tang M
    Int J Med Sci; 2021; 18(3):626-638. PubMed ID: 33437197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theranostic and nanotheranostic probes in nuclear medicine.
    Drude N; Tienken L; Mottaghy FM
    Methods; 2017 Nov; 130():14-22. PubMed ID: 28698069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear medicine in the era of personalised medicine.
    Lee ST; Scott AM
    Intern Med J; 2018 May; 48(5):497-499. PubMed ID: 29722186
    [No Abstract]   [Full Text] [Related]  

  • 15. Theranostic Radiopharmaceuticals: A Universal Challenging Educational Paradigm in Nuclear Medicine.
    Urbain JL; Scott AM; Lee ST; Buscombe J; Weston C; Hatazawa J; Kinuya S; Singh B; Haidar M; Ross A; Lamoureux F; Kunikowska J; Wadsak W; Dierckx R; Paez D; Giammarile F; Lee KH; O JH; Moshe M; Louw L; More S; Nadel H; Lee D; Wahl R
    J Nucl Med; 2023 Jun; 64(6):986-991. PubMed ID: 37142302
    [No Abstract]   [Full Text] [Related]  

  • 16. Alpha emitting nuclides in nuclear medicine theranostics.
    Miederer M
    Nuklearmedizin; 2022 Jun; 61(3):273-279. PubMed ID: 34624903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.
    Duan H; Iagaru A; Aparici CM
    Nanotheranostics; 2022; 6(1):103-117. PubMed ID: 34976584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
    Kulkarni HR; Singh A; Langbein T; Schuchardt C; Mueller D; Zhang J; Lehmann C; Baum RP
    Br J Radiol; 2018 Nov; 91(1091):20180308. PubMed ID: 29762048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear medicine theranostics comes of age.
    Herrmann K; Kraus BJ; Hadaschik B; Kunikowska J; van Poppel H; N'Dow J; Sartor O; Oyen WJG
    Lancet Oncol; 2021 Nov; 22(11):1497-1498. PubMed ID: 34735807
    [No Abstract]   [Full Text] [Related]  

  • 20. The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors.
    Pruis IJ; van Dongen GAMS; Veldhuijzen van Zanten SEM
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.